Voyager Therapeutics, Inc.
Revenue breakdown: Single Reportable Segment (100%).
8-K
Voyager Therapeutics, Inc. filed an 8-K on March 9, 2026, under Item 2.02 with Exhibit 99.1 furnished, indicating results of operations or earnings disclosure. Item 2.02 and Exhibit 99.1 are not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.